Petrelintide in ZUPREME-2: Weight Loss, Gut Tolerability and the Next Amylin Test

Petrelintide produced mean weight loss of 7.4% to 9.2% over 28 weeks in a Phase 2b diabetes trial, compared with 2.0% for placebo. The developer also reported few withdrawals because of gastrointestinal side effects. Both figures come from a Zealand Pharma company announcement dated October 7, 2026. The full results had not been peer-reviewed when the announcement went out.

ZUPREME-2 was a randomized, double-blind, placebo-controlled study in 220 US adults. Every participant had overweight or obesity plus type 2 diabetes. Three once-weekly petrelintide arms were tested against placebo. All groups followed a reduced-calorie diet with increased activity. Zealand Pharma is developing the investigational amylin analogue with Roche. This article sets out the topline numbers, the limits on what they can prove, and the larger trials now planned.

petrelintide: the ZUPREME-2 weight loss numbers

Zealand Pharma reported mean body-weight losses of 7.4% to 9.2% across its three petrelintide treatment arms at 28 weeks. The placebo group lost 2.0% on average over the same period. The range reflects three different dose arms rather than a single dose. That spread gives an early picture of dose response in this population.

Blood-sugar results moved in the same direction. HbA1c fell by as much as 0.65 percentage points in one petrelintide group. The placebo group saw HbA1c rise by 0.23 points over 28 weeks. Weight and glucose are separate endpoints. A result on one does not guarantee a result on the other. Each needs its own assessment.

The company also reported gastrointestinal-related treatment discontinuation of 1.9% for petrelintide and 1.7% for placebo. Zealand described those figures as low. They come from 220 people followed for 28 weeks. Larger and longer studies will say more about how the numbers hold up.

One detail matters when you read these figures. Zealand said the weight results reflect the company’s stated efficacy estimand. In plain terms, that is the treatment effect under the company’s chosen analysis rules. Other analysis choices can give different numbers. Group averages describe the study population. They do not forecast what one person would experience. The announcement did not report what happened after the 28-week treatment period ended. Source: Zealand Pharma, ZUPREME-2 company announcement, October 7, 2026; trial identifier NCT06926842.

How the 28-week study was run

ZUPREME-2 enrolled 220 adults with overweight or obesity and type 2 diabetes. Participants were taking metformin, sometimes with an SGLT2 inhibitor. That background therapy stayed in place during the trial. The population was a treated diabetes group. It was not a newly diagnosed or drug-naive population.

The design was randomized, double-blind and placebo-controlled. Three once-weekly petrelintide arms were compared with placebo. Every group followed a reduced-calorie diet and increased activity. Lifestyle change was a co-intervention in all arms. The placebo group’s 2.0% mean loss partly reflects that shared programme. Drug trials in obesity almost always include it.

The main readouts came at 28 weeks. Investigators tracked body-weight change, HbA1c change and discontinuation for gastrointestinal events. Twenty-eight weeks is a short window for a weight-management programme, where longer follow-up is the norm for assessing durability. A Phase 2b result can signal. It cannot settle long-term effects.

How to read a company topline announcement

A topline announcement is a developer’s summary of selected prespecified endpoints. It is not the full dataset. Companies release it to investors and the public before the detailed results appear. The detail usually follows at a scientific meeting. Peer-reviewed publication comes later still.

That sequence shapes what you can conclude. Topline numbers are company-reported. Independent researchers have not yet checked the analysis. Subgroup results, safety tables and dropout details stay unpublished until the full presentation. Zealand Pharma said the full ZUPREME-2 dataset had not been presented at a scientific meeting when the October 7 announcement went out.

What does an amylin weight loss drug do?

Amylin is a hormone released from pancreatic beta cells alongside insulin after eating. It helps regulate fullness and other parts of the meal response. Petrelintide is a long-acting amylin analogue. It was designed for once-weekly investigation in clinical trials.

The idea is to activate the amylin pathway for longer than the body’s own hormone lasts. Researchers want to know whether that steadier signal helps people eat less. An earlier amylin analogue, pramlintide, is approved in the US as a mealtime diabetes medicine. Petrelintide is a separate investigational compound. Approval of one medicine says nothing about another.

Amylin is one of several hormone pathways now studied in obesity. GLP-1 drugs brought the first wave of large weight reductions. Attention has since spread to GIP, glucagon and amylin signalling. Companies are testing which combinations give useful weight loss with manageable side effects. That work is still early. A promising mechanism or Phase 2 result does not equal an approved treatment.

Why the obesity field is watching amylin

The incretin era raised the bar for weight-loss medicines. It also exposed a gap. Many patients stop treatment because of gastrointestinal side effects. A pathway with a gentler stomach profile would matter in practice. That is the hope behind amylin research.

Zealand’s GI discontinuation figures drew attention for this reason. A 1.9% rate against 1.7% for placebo looks close. But discontinuation is only one tolerability measure. It says nothing about how many people felt nausea and kept going. Analysts noticed the gap too.

On October 8, BioSpace described William Blair analysts’ reaction to the data. They found the weight reduction interesting. They were underwhelmed by the glycemic effect. That is market commentary. It sits apart from the trial’s prespecified findings. Still, it explains why blood-sugar performance now faces scrutiny. A diabetes-trial population invites that question.

Does “placebo-level stomach dropouts” mean a weight loss drug without nausea?

No. GI-related discontinuation counts people who stopped trial treatment because of a digestive adverse event. It does not count everyone who felt nausea, vomiting or diarrhea. Many people continue treatment through mild symptoms. Their experience never appears in a discontinuation rate.

Zealand said gastrointestinal events were among the most commonly reported effects. The company described them as generally mild. Most clustered during dose escalation. Dose escalation exists so tolerability can be assessed gradually as the dose rises.

The 1.9% versus 1.7% comparison is encouraging as a trial observation. It cannot support a claim of no nausea. It cannot show the same overall GI event rate as placebo. The trial lasted 28 weeks and included 220 people. Rare harms need larger numbers. Longer-term tolerability needs longer follow-up. How people fare outside controlled trials is a separate question entirely.

petrelintide vs tirzepatide: what can be compared?

Readers naturally place ZUPREME-2 beside published tirzepatide results. The comparison is tempting. It is also unreliable. These figures do not come from a direct randomized comparison.

Trial populations differ. Diabetes status differs. Study length differs. Baseline weight, background medicines and diet programmes differ. Any one of those can shift a weight-loss number. Cross-trial math cannot settle which treatment performs better.

Analysts have added a second caution. Several found petrelintide’s blood-glucose improvement less compelling than competing diabetes treatments. BioSpace reported on October 8 that William Blair analysts were interested in the weight data but underwhelmed by the glycemic effect. Investors watch glucose because ZUPREME-2 enrolled people with type 2 diabetes. A diabetes population raises expectations for HbA1c. Whether that expectation is fair to an amylin analogue is a scientific question. The Phase 3 programme may answer it.

Where the petrelintide research goes next

Zealand Pharma and Roche have started a Phase 3a programme with three trials: ZUPREME-3, ZUPREME-4 and ZUPREME-5. Together they are expected to enrol roughly 7,000 people. The trials will cover groups with and without type 2 diabetes. One will include people with established cardiovascular disease. That step-up in size and scope is what Phase 2b cannot provide.

Longer trials can answer questions the 28-week study left open. They can track weight beyond six months. They can detect rarer adverse events. They can test the medicine in people without diabetes, where glucose effects matter less. One Phase 3a trial includes people with established cardiovascular disease. That is a start on broader populations, not a full outcomes programme.

The companies also described a Phase 2 combination study. It would pair petrelintide with Roche’s dual incretin agonist enicepatide, also known as CT-388. Combination trials test whether two pathways together do more than one alone. Enrollment plans and trial listings may change. No combination benefit can be assumed until its trial reports results.

Petrelintide remains investigational. It has no marketing authorization. It is not offered for sale on this site. Source: Zealand Pharma Phase 3 programme announcement, September 22, 2026.

— BT Staff